HIMS Stock Recent News

Hims & Hers may not be hurt by GLP-1 news the way investors think.

These top stocks are on a winning streak and have the businesses to keep it going.

Quint Tatro, Joule FInancial president, joins 'Power Lunch' to discuss stock plays for three stocks.

Shares of Hims & Hers Health (HIMS) sank Thursday after the Food and Drug Administration (FDA) said Eli Lilly's (LLY) popular weight-loss treatments, Mounjaro and Zepbound, were no longer on its list of drugs in short supply.

Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in the last 12 months and by 112% this year, outperforming the benchmark Nasdaq 100 and S&P 500 indices and other companies in the healthcare industry.

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $16.44, representing a +0.86% change from its previous close.

While it is no secret that assets in the stock market can offer substantial profits to skillful investors and traders, it is sometimes difficult to discern which stocks are better than others in this regard and which could provide an income of, say, $10,000 from investing a mere $1,000 in them.

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular weight-loss drug Wegovy to patients in certain professions for $99 a month.